253 related articles for article (PubMed ID: 16260697)
1. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
Kaufmann R; Spieth K; Leiter U; Mauch C; von den Driesch P; Vogt T; Linse R; Tilgen W; Schadendorf D; Becker JC; Sebastian G; Krengel S; Kretschmer L; Garbe C; Dummer R;
J Clin Oncol; 2005 Dec; 23(35):9001-7. PubMed ID: 16260697
[TBL] [Abstract][Full Text] [Related]
2. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D
Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Agarwala SS; Kirkwood JM
Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Ranson M; Hersey P; Thompson D; Beith J; McArthur GA; Haydon A; Davis ID; Kefford RF; Mortimer P; Harris PA; Baka S; Seebaran A; Sabharwal A; Watson AJ; Margison GP; Middleton MR
J Clin Oncol; 2007 Jun; 25(18):2540-5. PubMed ID: 17577032
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
[TBL] [Abstract][Full Text] [Related]
8. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide and cisplatin in avdanced malignant melanoma.
Daponte A; Ascierto PA; Gravina A; Melucci M; Scala S; Ottaiano A; Simeone E; Palmieris G; Comella G
Anticancer Res; 2005; 25(2B):1441-7. PubMed ID: 15865103
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
Guillot B; Khamari A; Cupissol D; Delaunay M; Bedane C; Dreno B; Picot MC; Dereure O
Melanoma Res; 2008 Apr; 18(2):141-6. PubMed ID: 18337651
[TBL] [Abstract][Full Text] [Related]
12. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup.
Ridolfi R; Romanini A; Sileni VC; Michiara M; Guida M; Biasco G; Poletti P; Amaducci L; Leoni M; Ravaioli A
Melanoma Res; 2004 Aug; 14(4):295-9. PubMed ID: 15305161
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
Falkson CI; Ibrahim J; Kirkwood JM; Coates AS; Atkins MB; Blum RH
J Clin Oncol; 1998 May; 16(5):1743-51. PubMed ID: 9586887
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
17. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
[TBL] [Abstract][Full Text] [Related]
18. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
[TBL] [Abstract][Full Text] [Related]
19. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
[TBL] [Abstract][Full Text] [Related]
20. A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
Coker SA; Dandamudi UB; Beelen AP; Crosby NA; Fisher JL; Obrocea M; Ernstoff MS; Lewis LD
J Chemother; 2013 Dec; 25(6):362-8. PubMed ID: 24093213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
